The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

In an interview with BioPharma Dive, the veteran biotech CEO said there remains a “significant opportunity” for young ...

The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic ...